Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 2Phase 1/2 1Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 7Lymphoid 3Head & Neck 3Thoracic 2Genitourinary 2Dermatologic 2Breast 2Tumor-Agnostic 1Sarcoma 1Other hematologic neoplasm 1Gynecologic 1

Conditions

Carcinoma, Ductal, Breast 1Breast Neoplasms 1

Interventions

Trastuzumab 349Paclitaxel 310Cyclophosphamide 286Docetaxel 267Carboplatin 215Capecitabine 214Letrozole 185Fulvestrant 178Doxorubicin 166Bevacizumab 136Anastrozole 120Tamoxifen 117pertuzumab 114pembrolizumab 113Epirubicin 110exemestane 107Vinorelbine 106Gemcitabine 106Albumin-Bound Paclitaxel 92Lapatinib 84130-nm albumin-bound paclitaxel 83Radiotherapy 79palbociclib 75eribulin 73Cisplatin 69pyrotinib 66Taxes 65Everolimus 55Goserelin 50Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Pharmaceutical Preparations × Breast × Clear all
NCT06207734 2025-05-01

Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2 Recruiting
120 enrolled
Breast

Breast Neoplasms

NCT01891357 2019-09-17

Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer

West German Study Group

Phase 2 Terminated
64 enrolled 7 charts
Breast

Carcinoma, Ductal, Breast

Data powered by HemOnc (CC BY 4.0) Colophon âš¡